<DOC>
	<DOCNO>NCT00991796</DOCNO>
	<brief_summary>The purpose study determine effect toxicity addition CS 1008 platinum base chemotherapy regimen progression-free survival ( PFS ) subject stage IIIB wet stage IV NSCLC .</brief_summary>
	<brief_title>CS-1008 With Carboplatin/Paclitaxel Chemotherapy na√Øve Subjects With Metastatic Unresectable Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>At least 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable disease define RECIST criterion Adequate organ bone marrow function evidence : Hemoglobin &gt; = 9 g/dL ; ANC &gt; = 1.5 x 109/L ; Platelet count &gt; = 100 x 109/L ; Serum creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 60 mL/min ; AST , ALT , alkaline phosphatase &lt; = 2.5 x upper limit normal ( ULN ) without liver metastasis &lt; = 5.0 x ULN liver metastasis ; Total bilirubin &lt; = 2.0 x ULN . Men woman childbearing potential must willing consent use effective double barrier contraception ( eg , hormonal contraceptive , bilateral tubal ligation , barrier spermicidal , intrauterine device ) treatment 3 month thereafter . All female subject childbearing potential must negative pregnancy test ( serum urine ) result &lt; = 72 hour initiate study treatment . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IEC approve ICF performance study specific procedure test . Anticipation need major surgical procedure radiotherapy ( RT ) study . Prior treatment chemotherapy disease . History follow condition within 6 month study enrolment : myocardial infarction ; New York Heart Association ( NYHA ) class II higher severe/unstable angina pectoris ; coronary/peripheral artery bypass graft ; NYHA class III IV congestive heart failure ; cerebrovascular accident transient ischemic attack , pulmonary embolism , clinically significant thromboembolic event ; clinically significant pulmonary disease ( eg , severe chronic obstructive pulmonary disease asthma ) ; clinically significant pulmonary edema anasarca.. See Section 17.2 NYHA Classification . Clinically significant pleural pericardial effusion . Grade 2 high current peripheral neuropathy ( See Section 17.3 ; NCI CTCAE , Version 3.0 ) . Clinically active brain metastasis ( ie , untreated , still require therapy steroid RT , progression within 4 week completion RT ) ; uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis . History malignancy NSCLC , unless expectation malignancy cure , tumor specific treatment malignancy administer within previous 5 year . Clinically significant active infection require antibiotic therapy Human Immunodeficiency Virus ( HIV ) positive subject receive antiretroviral therapy . Previous treatment chemotherapy , CS 1008 , agonistic DR 5 DR 4 antibody , TRAIL . Pregnant breast feeding . Known history hypersensitivity reaction component CS 1008 , carboplatin , paclitaxel formulation . Serious intercurrent medical psychiatric illness condition opinion Investigator would impair ability give inform consent unacceptably reduce protocol compliance safety study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>